News | November 10, 2021
Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
It plans to double its network to 50 centres across India in the next three years
More than 90,000 patients utilise the services daily
Its store network grew from 144 stores in March 2019 to 236 stores. It has a presence in 23 cities across Maharashtra, Goa and Karnataka, employing more than 4,600 people.
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
_256_384.jpg)
In the period April to August 2021, exports stood at Rs 73,469.29 crores compared to Rs 72,275.22 crores for the period April to August 2020 a growth of 1.65 per cent
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Subscribe To Our Newsletter & Stay Updated
